Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Youssra Salhi"'
Autor:
Chantal F. Stockem, Sarah M. H. Einerhand, Isabel Miras Rodríguez, Youssra Salhi, Esther Pérez, Dimitra R. Bakaloudi, Rafee Talukder, Belen Caramelo, Rafael Morales-Barrera, Astrid De Meulenaere, Alessandro Rametta, Andrea Bottelli, Felix Lefort, Patrizia Giannatempo, Christof Vulsteke, Joan Carles, Ignacio Duran, Petros Grivas, Alfonso Gómez de Liaño, Debbie G. J. Robbrecht, Begoña P. Valderrama, Vincent van der Noort, Michiel S. van der Heijden
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-8 (2024)
Abstract Background Anti-PD-(L)1 agent are approved as first- and second-line treatment options in advanced urothelial cancer (UC), but information about long-term survival is scarce. There is a need for prognostic factors, as these may help in the d
Externí odkaz:
https://doaj.org/article/567d40a068b9449d86c2a2294518a0e0
Autor:
Ignace H. J. T. de Hingh, Jurriaan B. Tuynman, Nina R. Sluiter, Henk M.W. Verheul, Veerle M.H. Coupé, Stijn L. Vlek, Youssra Salhi, Koen P. Rovers, Geert Kazemier
Publikováno v:
Annals of Surgical Oncology
Sluiter, N R, Rovers, K P, Salhi, Y, Vlek, S L, Coupé, V M H, Verheul, H M W, Kazemier, G, de Hingh, I H J T & Tuynman, J B 2018, ' Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC ', Annals of Surgical Oncology, vol. 25, no. 8, pp. 2347-2356 . https://doi.org/10.1245/s10434-018-6539-x
Annals of Surgical Oncology, 25(8), 2347-2356. Springer New York
Sluiter, N R, Rovers, K P, Salhi, Y, Vlek, S L, Coupé, V M H, Verheul, H M W, Kazemier, G, de Hingh, I H J T & Tuynman, J B 2018, ' Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC ', Annals of Surgical Oncology, vol. 25, no. 8, pp. 2347-2356 . https://doi.org/10.1245/s10434-018-6539-x
Annals of Surgical Oncology, 25(8), 2347-2356. Springer New York
Introduction: Cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) improve the survival of colorectal cancer (CRC) patients with peritoneal metastases. Patient selection is key since this treatment is associated with high morbidity. Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b22b6fba72774b6dee9c998e263a32a2
https://pubmed.ncbi.nlm.nih.gov/30302638
https://pubmed.ncbi.nlm.nih.gov/30302638